Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CrownBio Acquires PRECOS | Contract Pharma

What are you searching for?

Sign in
Breaking News

CrownBio Acquires PRECOS

Expands oncology expertise

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crown Bioscience, Inc. has acquired Preclinical Oncology Services Ltd. (PRECOS), a preclinical service provider with expertise in oncology. As a result of the acquisition, Crown will be among the largest suppliers of oncology services with a global footprint spanning North America, Europe and Asia Pacific.
 
CrownBio provides translational platforms and drug discovery solutions in the therapeutic areas of oncology and metabolic disease. Headquartered in Santa Clara, CA, the company also has research facilities in Kannapolis, NC, Beijing and Taicang, China. PRECOS provides reproducible, patient-relevant in vivo and in vitro oncology models as a business unit of the University of Nottingham, UK. In 2010 PRECOS became fully independent to provide commercial service to clients.
 
Jean-Pierre Wery, president of Crown Bioscience, remarked, “The acquisition represents the next step in expanding the range of specialized services we offer pharmaceutical and biopharmaceutical customers worldwide. PRECOS has unique clinically relevant models, which reflect the patient situation for each aspect of cancer progression, encompassing pre-cancerous lesions, primary tumors and metastasis.”
 
Neil Rotherham, chairman of PRECOS, added, “The acquisition will enable PRECOS to continue expanding its business as part of a larger organization, giving Crown Bioscience clients access to our unique and growing panel of Patient-Derived Xenograft, orthotopic and metastatic modeling and imaging services. The security of being part of a larger, global and rapidly growing organization will enable us to continue to invest in providing leading-edge model development services to the wider oncology drug discovery community.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics